Development asset linked to Iovance Biotherapeutics in public FDA and regional records.
pharma · Metastatic Melanoma · Unresectable Melanoma · IOVA
Iovance Biotherapeutics
Iovance Biotherapeutics B.V.
Iovance Biotherapeutics drug portfolio — 26 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
825 Industrial Rd, Suite 400, San Carlos, California 94070, US HQ
2007 Founded
916 Employees
Public company Type
IOVA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 825 Industrial Rd, Suite 400, San Carlos, California 94070, US
- Founded
- 2007
- Employees
- 916
- Programs
- 36
- Drugs
- 26
- Patents
- 94
Iovance Biotherapeutics pipeline
Portfolio lens on 26 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Iovance Biotherapeutics drug portfolio — 26 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved. Molecular target: Interleukin-2 receptor.
- Target
- Interleukin-2 receptor
- Mechanism
- Interleukin-2 receptor agonist
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Iovance Biotherapeutics's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Iovance Biotherapeutics in public FDA and regional records.
-
autologous glioma tumor cell lysates (inactivated)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Iovance Biotherapeutics's portfolio.
-
US regulatory status: approved. Mechanism: Surfactant agent.
- Mechanism
- Surfactant agent
-
Development asset linked to Iovance Biotherapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Iovance Biotherapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
- Target
- DNA polymerase (alpha/delta/epsilon)
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Iovance Biotherapeutics in public FDA and regional records.
-
Development asset linked to Iovance Biotherapeutics in public FDA and regional records.
-
Development asset linked to Iovance Biotherapeutics in public FDA and regional records.
-
Development asset linked to Iovance Biotherapeutics in public FDA and regional records.
-
ipilimumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
-
lifileucel
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Iovance Biotherapeutics's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
Development asset linked to Iovance Biotherapeutics in public FDA and regional records.
-
mannitol
Respiratory system (R05)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Iovance Biotherapeutics in public FDA and regional records.
-
Development asset linked to Iovance Biotherapeutics in public FDA and regional records.
-
Development asset linked to Iovance Biotherapeutics in public FDA and regional records.
-
Development asset linked to Iovance Biotherapeutics in public FDA and regional records.